Compare · AARD vs AZN
AARD vs AZN
Side-by-side comparison of Aardvark Therapeutics Inc. (AARD) and AstraZeneca PLC (AZN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AARD and AZN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $282.65B, about 11227.5x AARD ($25.2M).
- AZN has been more active in the news (22 items in the past 4 weeks vs 7 for AARD).
- AZN has more recent analyst coverage (25 ratings vs 17 for AARD).
- Company
- Aardvark Therapeutics Inc.
- AstraZeneca PLC
- Price
- -
- -
- Market cap
- $25.2M
- $282.65B
- 1M return
- -
- +11.17%
- 1Y return
- -
- +103.51%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- 2026
- News (4w)
- 7
- 22
- Recent ratings
- 17
- 25
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Latest AARD
- Aardvark Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Aardvark Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates
- SEC Form 10-Q filed by Aardvark Therapeutics Inc.
- Chief Executive Officer Lee Tien-Li was granted 793,951 stock options and returned 793,951 stock options to the company (SEC Form 4)
- Officer Sun Nelson was granted 304,094 stock options and returned 304,094 stock options to the company (SEC Form 4)
- Chief Medical Officer Jaiman Manasi was granted 374,560 stock options and returned 374,560 stock options to the company (SEC Form 4)
- Aardvark Therapeutics downgraded by Raymond James
- SEC Form 8-K filed by Aardvark Therapeutics Inc.
- Aardvark Therapeutics Reports Exploratory Data from the Terminated HERO and Open-Label Extension Trials
- SEC Form 8-K filed by Aardvark Therapeutics Inc.
Latest AZN
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- Perioperative IMFINZI® (durvalumab) approved in the US in novel regimen with neoadjuvant enfortumab vedotin-ejfv for patients with muscle-invasive bladder cancer
- FDA Approval for KLYGEFA issued to ALEXION PHARM
- AstraZeneca awards $1.6 million for programs to improve access to healthcare for patients across the US
- Officer Sharma Mani was granted 1 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,292 units (SEC Form 4)
- Gabelli Releases Agenda for 8th Annual Healthcare Symposium
- SEC Form 6-K filed by AstraZeneca PLC